XOMA vs. VSTM, VNDA, EBS, MACK, RIGL, RGLS, SYRS, LXRX, CUE, and OPK
Should you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Syros Pharmaceuticals (SYRS), Lexicon Pharmaceuticals (LXRX), Cue Biopharma (CUE), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -886.91%. Verastem's return on equity of -25.17% beat XOMA's return on equity.
Verastem received 164 more outperform votes than XOMA when rated by MarketBeat users. However, 65.95% of users gave XOMA an outperform vote while only 65.20% of users gave Verastem an outperform vote.
XOMA has higher revenue and earnings than Verastem. XOMA is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Verastem has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
In the previous week, XOMA had 8 more articles in the media than Verastem. MarketBeat recorded 9 mentions for XOMA and 1 mentions for Verastem. Verastem's average media sentiment score of 0.48 beat XOMA's score of 0.00 indicating that XOMA is being referred to more favorably in the news media.
Verastem presently has a consensus target price of $28.79, indicating a potential upside of 152.51%. XOMA has a consensus target price of $57.00, indicating a potential upside of 135.54%. Given XOMA's higher possible upside, equities research analysts clearly believe Verastem is more favorable than XOMA.
88.4% of Verastem shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 2.2% of Verastem shares are held by company insiders. Comparatively, 7.2% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
XOMA beats Verastem on 10 of the 17 factors compared between the two stocks.
Get XOMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
